Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 34 von 35 | SupStack

Metformin – Forschungsarchiv

Studien 2601–2650 von 2685, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

2601RCT1998

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS · Diabetes Care (1998)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.

Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus.

[Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].

Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin.

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.

Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease.

Effect of metformin on food intake in obese subjects.

The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients.

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

Metformin and exercise: no additive effect on blood lactate levels in health volunteers.

Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease.

Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients.

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.

Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

Different effect of acute and chronic oral metformin administration on glucose and insulin response to bread and to pasta in non-insulin dependent diabetic patients.

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients.

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance.

Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man.

Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.

Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

Influence of food on the disposition of the antidiabetic drug metformin in diabetic patients at steady-state.

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.

Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.

Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus.

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis.

Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man.

Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man.

Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes.

Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control.

The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men.

One year comparative trial of metformin and glipizide in type 2 diabetes mellitus.

Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes.

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

Metformin and metoprolol CR treatment in non-obese men.

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.